Search clinical trials for: AZD8165

Total 85 results

AstraZeneca

Terminated

Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects

Thrombin Inhibition

United States
AstraZeneca

Completed

To Evaluate the Bioavailability of a Tablet of AZD1656

Type 1 Diabetes

United States
AstraZeneca

Completed

Study to Assess the Absorption, Distribution, Metabolism and Excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM) (ADME)

Type II Diabetes Mellitus

United States
Cancer Research UK
AstraZeneca

Completed

A Phase I Trial of AZD3965 in Patients With Advanced Cancer

Adult Solid Tumor | Burkitt Lymphoma | Diffuse Large B Cell Lymphoma

United Kingdom
AstraZeneca
Parexel

Completed

A Study to Evaluate the Safety, Tolerability and Absorption to the Blood After Administration of Single and Multiple Doses of AZD8154 in Healthy Participants.

Asthma

Germany
AstraZeneca

Completed

A Study to Evaluate Safety and Tolerability After Oral Dosing of AZD1656 in Healthy Volunteers

Healthy

United States
AstraZeneca

Completed

A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes (MAD)

Type 2 Diabetes

United States
AstraZeneca

Completed

To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients

Glucose Lowering

United States
AstraZeneca

Completed

A Study to Evaluate Safety and Tolerability After Single Oral Dosing of AZD1656 in Japanese Healthy Volunteers

Healthy Volunteers

United States
AstraZeneca
Parexel

Recruiting

A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers

Healthy Volunteers

United States, Germany
St George Street Capital

Completed

AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19 (ARCADIA)

Covid19

Czechia, Romania, United Kingdom
AstraZeneca

Withdrawn

AZD8075 Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses of AZD8075 in Healthy Male Volunteers

Healthy
AstraZeneca

Terminated

A Single and Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Japanese Subjects (JSMAD)

Healthy

United Kingdom
AstraZeneca

Completed

To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients (JMAD)

Type 2 Diabetes

Japan
Queen Mary University of London
AstraZeneca

Active, not recruiting

AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNce (ADOPTION)

Diabetes Mellitus, Type 2 | End Stage Renal Disease | Type 2 Diabetes | Renal Transplant | Kidney Transplant; Complications

United Kingdom
AstraZeneca

Completed

AZD8566 Food Effect/Microtracer Study

Healthy Volunteer Study

United Kingdom
AstraZeneca
Parexel

Terminated

Evaluation of AZD8154 Concentrations in Blood

Asthma

Germany
AstraZeneca

Completed

AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects (JSAD/JMAD)

Healthy

United States
AstraZeneca

Completed

Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

Japan
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients

Type 2 Diabetes Mellitus

United States
AstraZeneca

Terminated

AZD8075 Single Ascending Dose Study

Healthy Volunteers

Sweden
AstraZeneca
National Institute of Mental Health (NIMH)

Completed

This is a Study to Determine the Antidepressant Effects of AZD6765

Treatment Resistant Major Depressive Disorder

United States
AstraZeneca

Completed

Study to Assess the Distribution, Metabolism and Excretion of [14C]AZD6765 After a Single-Dose Intravenous Administration (AZD6765)

Major Depressive Disorder

United Kingdom
AstraZeneca

Recruiting

First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies

Breast Cancer | Ovarian Cancer | Endometrial Cancer | Biliary Tract Carcinoma

United States, Spain, Australia, United Kingdom, Korea, Republic of, Belgium, Canada, China, Japan, Taiwan, Thailand, Hungary, Poland, Netherlands
AstraZeneca
Parexel

Terminated

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects

Dyslipidemia

United States
AstraZeneca

Completed

AZD8186 First Time In Patient Ascending Dose Study

Advanced Castrate-resistant Prostate Cancer CRPC | Squamous Non-Small Cell Lung Cancer sqNSCLC | Triple Negative Breast Cancer TNBC

Spain, Canada, United States, United Kingdom
AstraZeneca

Terminated

A Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease

Healthy | COPD

Sweden
AstraZeneca

Completed

To Evaluate 24-hr Glucose After OD vs BD AZD1656

Type II Diabetes

United States
AstraZeneca

Completed

A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.

GERD With Erosive Esophagitis

Sweden, United States, France, Italy, United Kingdom, Germany, Denmark, Finland, Norway, Canada
AstraZeneca

Completed

AZD6765 for Treatment Resistant Depression

Depression

United States
AstraZeneca

Withdrawn

AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)

Healthy

United States
AstraZeneca

Completed

A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.

GERD Without Erosive Esophagitis

Sweden, United States, France, Italy, United Kingdom, Germany, Denmark, Finland, Norway, Canada
AstraZeneca

Completed

A Study of Tor Kinase Inhibitor in Advanced Tumors

Solid Tumors

United States, France, United Kingdom
AstraZeneca

Completed

AZD8108 SAD/MAD in Healthy Volunteers (AZD8108)

Healthy Volunteers

United States
AstraZeneca

Completed

AZD2115 Multiple Ascending Dose Study

Healthy

United Kingdom
AstraZeneca

Completed

To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Metformin

Type 2 Diabetes

United States, India
AstraZeneca

Completed

AZD9164 Single Ascending Dose Study in Healthy Male Subjects

Healthy

Sweden
AstraZeneca

Completed

Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses of AZD8566.

Healthy Volunteer

United Kingdom
AstraZeneca

Completed

Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes

Type II Diabetes

United States
AstraZeneca

Completed

Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

Type 2 Diabetes

United States
AstraZeneca

Completed

AZD6765 Severe Major Depressive Disorder (MDD) IV

Major Depressive Disorder

United States
AstraZeneca

Completed

AZD2115 Single Ascending Dose Study

Chronic Obstructive Pulmonary Disease | Lung Disease Causing Persistent Narrowing of the Airways

United Kingdom
AstraZeneca

Completed

To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin

Type 2 Diabetes

United States
AstraZeneca

Completed

Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea

Type II Diabetes Mellitus

United States
AstraZeneca

Completed

Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of AZD8566.

Pharmacokinetics

United Kingdom
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease (COPD)

United States
National Cancer Institute (NCI)

Completed

AZD8055 for Adults With Recurrent Gliomas

Glioblastoma Multiforme | Malignant Glioma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma | Brainstem Glioma

United States
AstraZeneca

Completed

Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055

Cancer | Solid Tumors | Advanced Solid Malignancies

Japan
AstraZeneca

Withdrawn

Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours

Cancer | Advanced Solid Tumours | Lymphomas
AstraZeneca

Completed

Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients

Cancer | Advanced Hepatocellular Carcinoma

Korea, Republic of, Hong Kong

3

Subscribe